Skip to main content

Table 2 IR of the CERO endpoint in all patients enrolled in UPLIFT® study on years 1 to 4 of the study

From: Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial

  Tiotropium (n = 2986) Control (n = 3006) Tiotropium/control
Year N (%) Patient -year IRa N (%) Patient-year IRa RR-year p-value
        (95 % CI)  
1 436 (15) 2711.4 16.1 556 (19) 2637.5 21.1 0.76 <0.0001
        (0.67–0.86)  
2 664 (22) 5146.1 12.9 803 (27) 4959.0 16.2 0.80 <0.0001
        (0.72–0.88)  
3 843 (28) 7373.7 11.4 992 (33) 7059.6 14.1 0.81 <0.0001
        (0.74–0.89)  
4 995 (33) 9442.9 10.5 1128 (38) 9007.5 12.5 0.84 0.0001
        (0.77–0.92)  
  1. N = number of events
  2. CI confidence interval, IR incidence rate, RR risk ratio
  3. aPer 100 patient-years